Amelia Wnorowski MD, Presenter: Nothing to Disclose

Flavius F. Guglielmo MD, Abstract Co-Author: Nothing to Disclose

Patrick L. O'Kane MD, Abstract Co-Author: Research Consultant, NPS Pharmaceuticals

Donald G. Mitchell MD, Abstract Co-Author: Consultant, CMC Contrast AB

1. The liver is usually the first metastatic site in uveal melanoma. There are common and uncommon appearances of liver metastases, some of which are almost unique to this disease. 2. There are common and uncommon locations of extrahepatic metastases. Many common locations of extrahepatic uveal melanoma metastases are infrequently seen with other malignancies. 3. Current therapies focus on controlling hepatic disease burden to improve survival. Imaging surveillance in these patients necessitates familiarity with the appearances of viable tumor and expected post-treatment change. 4. Abdominal MRI is particularly valuable in the diagnosis and follow-up of patients with metastatic uveal melanoma. 5. Awareness of the patterns of hepatic and extrahepatic uveal melanoma metastases can improve diagnostic accuracy.

Background 1. Uveal melanoma: Frequency of metastases, prognosis 2. Treatment options: Liver-directed therapy Hepatic Metastases 1. Available screening studies and utility of MRI 2. MRI a. Appearance on various sequences b. Hepatocyte-specific versus extracellular space contrast agents 3. Atypical metastatic patterns 4. Post-treatment evaluation Extrahepatic Metastases 1. Common locations 2. Uncommon locations 

http://abstract.rsna.org/uploads/2014/14003735/14003735_tbp8.pdf

Wnorowski, A, Guglielmo, F, O'Kane, P, Mitchell, D, Hepatic and Extrahepatic Metastatic Findings in Metastatic Uveal Melanoma: Making Sense of a Unique Malignancy.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14003735.html